



EXaCT-1 Whole Exome FDA Approved Therapies

Non Small Cell Lung Cancer

Bio Marker

EGFR exon 19 deletions
& **EGFR** exon 21 L858R alterations
EGFR exon 20 T790M alterations

BRAF V600E

FDA-Approved Therapy

Gilotrif® (afatinib), **Iressa**® (gefitinib),
or **Tarceva**® (erlotinib)

Tagrisso® (osimertinib)

Tafinlar® (dabrafenib) in combination
with **Mekinist**® (trametinib)

Melanoma

Bio Marker

BRAF V600E
BRAF V600E or V600K

FDA-Approved Therapy

Tafinlar® (dabrafenib) or **Zelboraf**® (vemurafenib)
Mekinist® (trametinib) or **Cotellic**® (cobimetinib), in
combination with **Zelboraf**® (vemurafenib)

Breast Cancer

Bio Marker

ERBB2 (HER2) amplification

FDA-Approved Therapy

Herceptin® (trastuzumab), **Kadcyla**®(ado-trastuzumab-emtansine), or **Perjeta**® (pertuzumab)

Colorectal

Bio Marker

KRAS wild-type (absence of mutations in codons 12 & 13)
KRAS wild-type (absence of mutations in exons 2, 3, and
4) and **NRAS** wild type (absence of mutations in exons 2, 3, and 4)

FDA-Approved Therapy

Erbitux® (cetuximab)
Vectibix® (panitumumab)